Autres langues Tengion, Inc.

Actions

TNGNQ

US88034G2084

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:30:19 22/09/2025			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	-.--%		+900,00 %	+9 900,00 %

20/11/23	Tengion, Inc. a cessé ses activités	CI
25/02/22	Changement de juge des faillites pour Tengion, Inc.	CI

Autres langues

20/11/23	Tengion, Inc. Went Out of Business
25/02/22	Bankruptcy Judge Changed for Tengion, Inc.
31/03/15	RegenMedTX, LLC completed the acquisition of substantially all assets from Tengion, Inc. (OTCPK:TNGN.Q).
06/03/15	Motion for Private Asset Sale Approved for Tengion, Inc.
20/02/15	Order Approving Private Sale Agreement for Tengion, Inc.
12/02/15	Motion for Asset Sale Filed by Chapter 7 Trustee for Tengion, Inc.
12/02/15	RegenMedTX, LLC signed an agreement to acquire substantially all assets from Tengion, Inc. (OTCPK:TNGN.Q) for $22.1 million.
31/12/14	Tengion, Inc. will Change its Ticker to TNGNQ from TNGN
29/12/14	Tengion, Inc. Filed for Bankruptcy
14/11/14	Tengion, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
22/09/14	Tengion Considers A Strategic Review
13/08/14	Tengion, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended June 30, 2014; Provides Clinical Update
15/05/14	Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014
26/03/14	Tengion, Inc. Auditor Raises 'Going Concern' Doubt
26/03/14	Tengion, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013
13/01/14	Tengion, Inc. Announces Continued Clinical Progress in its Two Lead Programs
14/08/13	Tengion, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2013
07/08/13	Tengion, Inc. Promotes A. Brian Davis to Chief Financial Officer and Senior Vice President, Finance
28/06/13	Tengion, Inc. announced that it has received $18.60 million in funding from a group of investors.
15/05/13	Tengion, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013
01/04/13	Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
26/03/13	Tengion, Inc. Auditor Raises 'Going Concern' Doubt
18/03/13	Tengion, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012
30/01/13	Tengion, Inc. Announces Clinical Progress for Neo-Urinary Conduit Phase 1 Trial and Regulatory Advance for Neo-Kidney Augment
21/12/12	Tengion, Inc. Announces Resignation of Scott D. Flora from Board of Directors